Loading fund…
Loading fund…
| Returns | 1D | 1M | 3M | YTD | 1Y | 3Y | 5Y | MAX |
|---|---|---|---|---|---|---|---|---|
| Total return | ▲ +2.2% | ▲ +4.5% | ▼ −12.7% | ▼ −15.4% | ▼ −17.0% | — | — | ▼ −51.8% |
| Peer average | — | — | — | — | — | — | — | — |
| S&P 500 · VOO | ▼ −0.4% | ▲ +0.9% | ▲ +3.3% | ▲ +13.8% | ▲ +13.3% | ▲ +88.8% | ▲ +81.9% | — |
This investment product primarily channels its resources, typically committing a minimum of 95% of its net assets, into American Depositary Receipts (ADRs) that represent the B Shares of Novo Nordisk A/S. It's crucial to understand that direct investment in the company's underlying shares is not part of this series' strategy. Additionally, the fund is structured as non-diversified, indicating a concentrated portfolio.
Distribution yield and SEC yield use different methodologies. Payouts may include income, capital gains, or return of capital.
| Ex-date | Pay date | Per share |
|---|---|---|
| 2026-09-16 | 2026-09-23 | $0.03 |
| 2026-06-16 | 2026-06-23 | $0.77 |
| 2026-03-16 | 2026-03-23 | $0.28 |
| 2025-12-16 | 2025-12-24 | $0.49 |
| 2025-09-16 | 2025-09-23 | $0.17 |
Estimated annual expense excludes trading costs and assumes constant assets. Fee waivers and fund costs can change.
Historical risk measures describe past behavior and do not predict future returns.
Hear the strategy from the people behind NVOH.